The Bufei Nashen Pill Alleviates COPD by Targeting Endoplasmic Reticulum Stress Through the PERK/eIF2α Signaling Pathway

Key Points

• To investigate how Bufei Nashen Pill affects endoplasmic reticulum stress in COPD.
• Administration of Bufei Nashen Pill
• Evaluation of endoplasmic reticulum stress markers
• Assessment of PERK/eIF2α pathway inhibition
• BFNSP effectively reduces markers of endoplasmic reticulum stress
• Suppression of the PERK/eIF2α signaling pathway observed
• Significant improvement in COPD symptoms noted